ORIC Pharmaceuticals expands inducement equity plan by 1.1 million shares

ORIC Pharmaceuticals disclosed in a Form 8-K that its board of directors approved an amended and restated 2022 Inducement Equity Incentive Plan effective July 28, 2026, in order to increase the number of shares reserved for issuance under the plan¹.

Under the amendment, the board reserved an additional 1,100,000 shares of common stock, bringing the total to 3,350,000 shares reserved in the aggregate for equity awards under the plan¹.

The company noted that the plan and its share increases were put in place without a stockholder vote, relying on the relevant Nasdaq listing rules that permit this for inducement plans¹.

The plan itself covers several types of equity compensation. According to the filing, it allows for stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units, with terms largely mirroring the company's 2020 Equity Incentive Plan, particularly around how awards are handled in a merger or change in control, while adding provisions needed to satisfy Nasdaq's rules for inducement awards or merger and acquisition situations¹.

Eligibility is limited under Nasdaq rules. The filing states that awards can go only to people who were not already ORIC employees or board members, or to such individuals after they have gone through a genuine break in service, with the awards serving as an inducement for them to join the company, or in some cases in connection with a merger or acquisition if Nasdaq rules allow it¹.

A copy of the plan and related agreement forms were filed as Exhibit 10.1. These documents are incorporated by reference into the 8-K¹. The filing was signed by Christian Kuhlen, the company's General Counsel, on July 30, 2026.